Studio E.R. Congressi

Monday, November 4, 2019

Session I: Genomic Landscapes

Chairmen: G. Gaidano, D. Rossi

CLL pathogenesis: microenviromental and genetics
D. Colomer
The role of microRNA in CLL pathogenesis
C.M. Croce
Predictive biomarkers
D. Rossi

Session II: Chemoimmunotherapy

Chairmen: M. Hallek, C. Tam

J.A. Burger
Chlorambucil plus anti-CD20
M. Hallek
Comorbidities and other cancers
A. Ferrajoli

Session III: Novel Targeted Therapies

Chairmen: P. Ghia, S.M. O’Brien

J.A. Burger
S.M. O’Brien
Second generation BTK Inhibitor
P. Hillmen
Management of side-effects during targeted therapy
M.S. Davids
Drivers of treatment patterns in patients stopping ibrutinib or idelalisib
A.R. Mato

Session IV: Richter Syndrome

Chairman: A. Cuneo

Is there a potential risk of an increased rate of Richter Syndrome with the advent of targeted therapy?
D. Rossi
Treatment approach in the era of novel therapies
T.A. Eyre

Session V: Further Innovative Therapeutical Approaches

Chairman: S.M. O’Brien

When and how to use allotransplant
P. Dreger

Tuesday, November 5, 2019

Session VI: Newer Agents

Chairmen: A.R. Mato, P.L. Zinzani

Next-generation BTK inhibitors: Zanubrutinib
C. Tam
Next-generation BTK inhibitors: ARQ531
D.M. Stephens
Other PI3K inhibitors: Duvelisib
S.M. O’Brien
Other PI3K inhibitors: Umbralisib
A.R. Mato

SESSION VII: Interesting Observations/Questions

Chairmen: J.A. Burger, R. Foà

The stop of the treatment with the new targeted therapies: will it be possible in the future?
P. Hillmen
Which are the best combinations of therapies using targeted agents?
J.A. Burger
How should we sequence these novel agents?
M.S. Davids

Studio E.R. Congressi s.r.l.
Via de' Poeti, 1
40124 Bologna BO
P.IVA 06301101009